GGrantIndex
← Leaderboards

Jennifer Jao

Icahn School Of Medicine At Mount Sinai

$11,042,167
Attributed
$23,135,868
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $22.4M · FY201225
$25M$18.8M$12.5M$6.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$119,511,410 · 9

By mechanism

P01$88,304,328 · 1
R01$18,651,038 · 3
U19$8,071,214 · 1
R33$2,504,560 · 1
R61$841,208 · 1
K23$646,762 · 1

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Others in their field

Top investigators on “Child

Research focus

ChildExposure ToAnti-Retroviral AgentsCohortPharmaceutical PreparationsIn UteroPregnant WomenResearch InfrastructureMetabolicInsulin ResistanceInfantAntiretroviral TherapyHiv InfectionsWomanPublic HealthFutureDesignAdolescentLifeRegimenCardiometabolismRisk FactorsLife Cycle StagesGrowth

Grant awards (39)

Pediatric HIV/AIDS Cohort Study (PHACS): Research on Immune Aging, Supporting Reproductive Health, and Perinatal Acquisition: Elucidating Relationships in HIV (RISE)$8,071,214
U19 · FY2025 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,732
P01 · FY2024 · HD
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)$2,452,419
R01 · FY2024 · HD
Understanding Inflammatory and Metabolic Pathways of Myocardial and Vascular Dysfunction in South African Youth Living with Perinatal HIV$638,591
R01 · FY2024 · HL · contact PI
FLOURISH - Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescent who are HIV Exposed Uninfected$587,293
R33 · FY2024 · HD
Disclosure Intervention to Support Caregivers (DISC)$336,391
R33 · FY2024 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$217,850
P01 · FY2024 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,816
P01 · FY2023 · HD
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)$2,717,846
R01 · FY2023 · HD
Understanding Inflammatory and Metabolic Pathways of Myocardial and Vascular Dysfunction in South African Youth Living with Perinatal HIV$693,765
R01 · FY2023 · HL · contact PI
FLOURISH - Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescent who are HIV Exposed Uninfected$612,768
R33 · FY2023 · HD
Admin Sup FACET: Family Dynamics and Child Neurodevelopment in Botswana$287,707
R33 · FY2023 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,600,741
P01 · FY2022 · HD
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)$2,491,998
R01 · FY2022 · HD
FLOURISH - Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescent who are HIV Exposed Uninfected$680,401
R33 · FY2022 · HD
Understanding Inflammatory and Metabolic Pathways of Myocardial and Vascular Dysfunction in South African Youth Living with Perinatal HIV$550,840
R01 · FY2022 · HL · contact PI
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,457,932
P01 · FY2021 · HD
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)$2,294,356
R01 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$803,491
P01 · FY2021 · HD
Understanding Inflammatory and Metabolic Pathways of Myocardial and Vascular Dysfunction in South African Youth Living with Perinatal HIV$656,604
R01 · FY2021 · HL · contact PI
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$450,000
P01 · FY2021 · HD
FLOURISH - Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescent who are HIV Exposed Uninfected$409,985
R61 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$322,285
P01 · FY2021 · HD
Pediatric HIV/AIDS Cohort Study (PHACS) 2020$17,150,481
P01 · FY2020 · HD
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)$2,382,926
R01 · FY2020 · HD
Understanding Inflammatory and Metabolic Pathways of Myocardial and Vascular Dysfunction in South African Youth Living with Perinatal HIV$733,852
R01 · FY2020 · HL · contact PI
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana$578,056
R01 · FY2020 · DK · contact PI
FLOURISH - Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescent who are HIV Exposed Uninfected$431,223
R61 · FY2020 · HD
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana$578,121
R01 · FY2019 · DK · contact PI
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana$629,835
R01 · FY2018 · DK · contact PI
Metabolomic Signatures of Insulin Resistance and Visceral Adiposity Changes in HIV-infected Adults on Newer Line Antiretroviral Therapy$140,873
R21 · FY2018 · DK · contact PI
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana$645,360
R01 · FY2017 · DK · contact PI
Metabolomic Signatures of Insulin Resistance and Visceral Adiposity Changes in HIV-infected Adults on Newer Line Antiretroviral Therapy$351,427
R21 · FY2017 · DK · contact PI
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-exposed uninfected in Botswana$606,469
R01 · FY2016 · DK · contact PI
Metabolic Effects of In Utero Antiretrovirals on HIV Exposed Uninfected Infants$129,346
K23 · FY2016 · HD · contact PI
Metabolic Effects of In Utero Antiretrovirals on HIV Exposed Uninfected Infants$129,354
K23 · FY2015 · HD · contact PI
Metabolic Effects of In Utero Antiretrovirals on HIV Exposed Uninfected Infants$129,354
K23 · FY2014 · HD · contact PI
Metabolic Effects of In Utero Antiretrovirals on HIV Exposed Uninfected Infants$129,354
K23 · FY2013 · HD · contact PI
Metabolic Effects of In Utero Antiretrovirals on HIV Exposed Uninfected Infants$129,354
K23 · FY2012 · HD · contact PI